N P Shankley
Overview
Explore the profile of N P Shankley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
715
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barrett T, Lagaud G, Wagaman P, Freedman J, Yan W, Andries L, et al.
Br J Pharmacol
. 2012 Feb;
166(5):1684-93.
PMID: 22300007
Background And Purpose: JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide] is a novel antagonist at cholecystokinin CCK(2) receptors with good pharmacokinetic properties and represents a novel mechanism for the treatment of gastro-oesophageal reflux disease (GORD)....
2.
Shankley N, Morton M, Watt G
Curr Protoc Pharmacol
. 2011 Oct;
Chapter 4:Unit4.17.
PMID: 21959758
This unit describes three standard in vitro bioassays for studying histamine H₁, H₂ and H₃ receptors in isolated intact tissues removed from the guinea pig. Both the H₁ and H₃...
3.
Black J, Leff P, Shankley N, Wood J
Br J Pharmacol
. 2010 Jul;
160 Suppl 1:S54-64.
PMID: 20590656
No abstract available.
4.
Barrett T, Yan W, Freedman J, Lagaud G, Breitenbucher J, Shankley N
Br J Pharmacol
. 2008 Feb;
153(8):1650-8.
PMID: 18297100
Background And Purpose: Cholecystokinin (CCK) stimulates the release of amylase and lipase from the normal pancreas. However, it is not clear to what extent this occurs in the early stages...
5.
HARPER E, Shankley N, Black J
Br J Pharmacol
. 2007 Mar;
151(1):128-43.
PMID: 17351664
Background And Purpose: Agonist apparent affinities (pK(I)') in histamine H(3)-receptor binding assays were higher than expected from apparent affinity values (pK(app)) estimated in bioassay. Here, we investigate whether the degree...
6.
Gerskowitch V, Hodge J, Hull R, Shankley N, Kalindjian S, McEwen J, et al.
Br J Clin Pharmacol
. 2006 Oct;
63(5):618-22.
PMID: 17052250
Unlabelled: WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT?: * Two chemically diverse CCK1 receptor antagonists have been shown clinically to inhibit CCK-evoked contraction of human gallbladder [2, 3]. These studies...
7.
Morton M, HARPER E, Tavares I, Shankley N
Br J Pharmacol
. 2003 Sep;
140(1):218-24.
PMID: 12967952
(1) The alternatively spliced, short and long cholecystokinin receptors (CCK2S and CCK2L) were expressed in NIH3T3 cells, and compared using radioligand-binding assays with identical buffer and incubation conditions. (2) As...
8.
Morton M, HARPER E, Tavares I, Shankley N
Br J Pharmacol
. 2002 Jul;
136(6):873-82.
PMID: 12110612
1. The pharmacology of the cholecystokinin CCK(1) receptors endogenously expressed in human gallbladder and human ascending colon smooth muscle tissue was compared using radioligand binding assays. 2. Saturation analysis of...
9.
Morton M, Welsh N, Tavares I, Shankley N
Regul Pept
. 2002 Feb;
105(1):59-64.
PMID: 11853872
Cholecystokinin (CCK) produces contractions of gallbladder and colon in a number of different species. Although the effects of CCK on the human gallbladder are relatively well documented, the CCK receptors...
10.
HARPER E, Lovenberg T, Shankley N, Black J
Inflamm Res
. 2001 Jun;
50 Suppl 2:S106-7.
PMID: 11411576
No abstract available.